Development and Validation of an Antibody for Detection of Lysine Homocysteinylation in Cobalamin Disorders

The National Institutes of Health OLAO issued this pre-solicitation notice, identified by solicitation number 75N98026Q00506, for the development and validation of a novel post-translational modification-specific antibody. This requirement involves the synthesis and purification of peptide antigens with N-homocysteinylated lysine residues and matched control peptides, which are then conjugated to carrier proteins for host immunization. The primary objective is to generate and purify a working polyclonal antibody from rabbit serum to detect N-homocysteine-lysine, as there is currently no commercially available alternative. This effort supports biomedical research on rare genetic diseases and the advancement of precision medicine.

The scope of work includes immunizing host species, generating polyclonal sera through antigen boosts, and testing the resulting sera on lab samples from mouse models and through ELISA screening. Once purified, the antibody will be used to characterize proteins affected by aberrant post-translational modification to assist in understanding disease development and designing future targeted therapies. The performance of these services is located in Maryland, USA, and corresponds with one attachment titled Requirement rev8.docx.

This opportunity is classified under NAICS code 541714 for Research and Development in Biotechnology (except Nanobiotechnology) and PSC code Q301 for MEDICAL- LABORATORY TESTING. The acquisition is designated as an SBA Small Business Administration set-aside. Responses are due by June 13, 2026, and the primary point of contact is John Burton.